Identification and treatment of latent tuberculosis infection (LTBI) can substantially reduce
the risk of developing active disease. However, there is no diagnostic gold standard for LTBI …

The aim of diagnostic point-of-care testing is to minimise the time to obtain a test result,
thereby allowing clinicians and patients to make a quick clinical decision. Because point-of …

Background Active pulmonary tuberculosis is difficult to diagnose and treatment response is
difficult to effectively monitor. A WHO consensus statement has called for new non-sputum …

Background Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new
antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro …

Tuberculosis (TB) is more prevalent in the world today than at any other time in human
history. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse …

SUMMARY A syndemic is defined as the convergence of two or more diseases that act
synergistically to magnify the burden of disease. The intersection and syndemic interaction …

Although progress has been made to reduce global incidence of drug-susceptible
tuberculosis, the emergence of multidrug-resistant (MDR) and extensively drug-resistant …

Rapid expansion of the standardised approach to tuberculosis diagnosis and treatment that
is recommended by WHO allowed more than 36 million people to be cured between 1995 …

Millions of cases of tuberculosis (TB) go undiagnosed each year. Better diagnostic tools are
urgently needed. Biomarker-based or multiple marker biosignature-based tests, ideally …

Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …